151 related articles for article (PubMed ID: 33452612)
61. Prostate-specific antigen and other serum and urine markers in prostate cancer.
Stephan C; Ralla B; Jung K
Biochim Biophys Acta; 2014 Aug; 1846(1):99-112. PubMed ID: 24727384
[TBL] [Abstract][Full Text] [Related]
62. Urinary Prostate Cancer Antigen 3 as a Tumour Marker: Biochemical and Clinical Aspects.
Schmid M; Hansen J; Chun FK
Adv Exp Med Biol; 2015; 867():277-89. PubMed ID: 26530372
[TBL] [Abstract][Full Text] [Related]
63. Novel biomarkers for risk of prostate cancer: results from a case-control study.
Yang L; Gaikwad NW; Meza J; Cavalieri EL; Muti P; Trock B; Rogan EG
Prostate; 2009 Jan; 69(1):41-8. PubMed ID: 18816637
[TBL] [Abstract][Full Text] [Related]
64. Urinary DNA Methylation Biomarkers for Noninvasive Prediction of Aggressive Disease in Patients with Prostate Cancer on Active Surveillance.
Zhao F; Olkhov-Mitsel E; van der Kwast T; Sykes J; Zdravic D; Venkateswaran V; Zlotta AR; Loblaw A; Fleshner NE; Klotz L; Vesprini D; Bapat B
J Urol; 2017 Feb; 197(2):335-341. PubMed ID: 27545574
[TBL] [Abstract][Full Text] [Related]
65. Expression of PCA3 and PSA genes as a biomarker for differential diagnosis of nodular hyperplasia and prostate cancer.
Coelho FF; Guimarães FL; Cabral WL; Salles PG; Mateo EC; Nogueira e Nogueira LM; Fonseca CE; Gomes KB
Genet Mol Res; 2015 Oct; 14(4):13519-31. PubMed ID: 26535666
[TBL] [Abstract][Full Text] [Related]
66. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.
Van Neste L; Hendriks RJ; Dijkstra S; Trooskens G; Cornel EB; Jannink SA; de Jong H; Hessels D; Smit FP; Melchers WJ; Leyten GH; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; Hulsbergen-van de Kaa CA; Mulders PF; van Oort IM; Van Criekinge W; Schalken JA
Eur Urol; 2016 Nov; 70(5):740-748. PubMed ID: 27108162
[TBL] [Abstract][Full Text] [Related]
67. The role of proteomics in prostate cancer research: biomarker discovery and validation.
Pin E; Fredolini C; Petricoin EF
Clin Biochem; 2013 Apr; 46(6):524-38. PubMed ID: 23266295
[TBL] [Abstract][Full Text] [Related]
68. Exosomal and Non-Exosomal Urinary miRNAs in Prostate Cancer Detection and Prognosis.
Foj L; Ferrer F; Serra M; Arévalo A; Gavagnach M; Giménez N; Filella X
Prostate; 2017 May; 77(6):573-583. PubMed ID: 27990656
[TBL] [Abstract][Full Text] [Related]
69. Measurement of urinary canine S100A8/A9 and S100A12 concentrations as candidate biomarkers of lower urinary tract neoplasia in dogs.
Heilmann RM; Wright ZM; Lanerie DJ; Suchodolski JS; Steiner JM
J Vet Diagn Invest; 2014 Jan; 26(1):104-12. PubMed ID: 24398905
[TBL] [Abstract][Full Text] [Related]
70. The present and future of prostate cancer urine biomarkers.
Rigau M; Olivan M; Garcia M; Sequeiros T; Montes M; Colás E; Llauradó M; Planas J; Torres Id; Morote J; Cooper C; Reventós J; Clark J; Doll A
Int J Mol Sci; 2013 Jun; 14(6):12620-49. PubMed ID: 23774836
[TBL] [Abstract][Full Text] [Related]
71. Prognostic accuracy of prostate health index and urinary prostate cancer antigen 3 in predicting pathologic features after radical prostatectomy.
Vlaeminck-Guillem V
Urol Oncol; 2015 Nov; 33(11):498. PubMed ID: 26116413
[No Abstract] [Full Text] [Related]
72. DNA methylation biomarkers of prostate cancer: confirmation of candidates and evidence urine is the most sensitive body fluid for non-invasive detection.
Payne SR; Serth J; Schostak M; Kamradt J; Strauss A; Thelen P; Model F; Day JK; Liebenberg V; Morotti A; Yamamura S; Lograsso J; Sledziewski A; Semjonow A
Prostate; 2009 Sep; 69(12):1257-69. PubMed ID: 19459176
[TBL] [Abstract][Full Text] [Related]
73. Integration of lipidomics and transcriptomics unravels aberrant lipid metabolism and defines cholesteryl oleate as potential biomarker of prostate cancer.
Li J; Ren S; Piao HL; Wang F; Yin P; Xu C; Lu X; Ye G; Shao Y; Yan M; Zhao X; Sun Y; Xu G
Sci Rep; 2016 Feb; 6():20984. PubMed ID: 26865432
[TBL] [Abstract][Full Text] [Related]
74. Next Generation Sequencing of urine exfoliated cells: an approach of prostate cancer microRNAs research.
Guelfi G; Cochetti G; Stefanetti V; Zampini D; Diverio S; Boni A; Mearini E
Sci Rep; 2018 May; 8(1):7111. PubMed ID: 29740090
[TBL] [Abstract][Full Text] [Related]
75. Construction and analysis of protein-protein interaction networks based on proteomics data of prostate cancer.
Chen C; Shen H; Zhang LG; Liu J; Cao XG; Yao AL; Kang SS; Gao WX; Han H; Cao FH; Li ZG
Int J Mol Med; 2016 Jun; 37(6):1576-86. PubMed ID: 27121963
[TBL] [Abstract][Full Text] [Related]
76. miRNAs as novel biomarkers in the management of prostate cancer.
Filella X; Foj L
Clin Chem Lab Med; 2017 May; 55(5):715-736. PubMed ID: 26751899
[TBL] [Abstract][Full Text] [Related]
77. Proteomics analysis of malignant and benign prostate tissue by 2D DIGE/MS reveals new insights into proteins involved in prostate cancer.
Davalieva K; Kostovska IM; Kiprijanovska S; Markoska K; Kubelka-Sabit K; Filipovski V; Stavridis S; Stankov O; Komina S; Petrusevska G; Polenakovic M
Prostate; 2015 Oct; 75(14):1586-600. PubMed ID: 26074449
[TBL] [Abstract][Full Text] [Related]
78. Hyaluronic acid and hyaluronidase as possible novel urine biomarkers for the diagnosis of prostate cancer.
Skarmoutsos I; Skarmoutsos A; Katafigiotis I; Tataki E; Giagini A; Adamakis I; Alamanis C; Duvdevani M; Sitaras N; Constantinides C
Med Oncol; 2018 May; 35(7):97. PubMed ID: 29802604
[TBL] [Abstract][Full Text] [Related]
79. Tissue Proteome Signatures Associated with Five Grades of Prostate Cancer and Benign Prostatic Hyperplasia.
Kawahara R; Recuero S; Nogueira FCS; Domont GB; Leite KRM; Srougi M; Thaysen-Andersen M; Palmisano G
Proteomics; 2019 Nov; 19(21-22):e1900174. PubMed ID: 31576646
[TBL] [Abstract][Full Text] [Related]
80. Frequent methylation of RASSF1 and RARB in urine sediments from patients with early stage prostate cancer.
Daniūnaitė K; Berezniakovas A; Jankevičius F; Laurinavičius A; Lazutka JR; Jarmalaitė S
Medicina (Kaunas); 2011; 47(3):147-53. PubMed ID: 21822036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
